Related Experiment Video

Updated: May 28, 2026

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

[Expression of P-glycoprotein and multidrug resistance-associated protein in peripheral blood mononuclear cells from

Zhan Lian1, Ping Wu, Jing Zhou

  • 1Institute of Tuberculosis, Wuhan Tuberculosis Prevention and Cure Institute, Wuhan, China.

Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|November 2, 2011
PubMed
Abstract

Insights

Multidrug-resistant tuberculosis (MDR-TB) patients show significantly higher multidrug resistance-associated protein (MRP) mRNA levels in peripheral blood mononuclear cells. P-glycoprotein (P-pg) mRNA levels did not differ significantly between groups.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health challenge.
  • Understanding the molecular mechanisms of drug resistance in TB is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the expression of P-glycoprotein (P-pg) and multidrug resistance-associated protein (MRP) mRNA in peripheral blood mononuclear cells (PBMCs) of MDR-TB patients.
  • To compare these expression levels with those in non-TB controls and drug-susceptible TB patients.

Main Methods:

  • Peripheral blood mononuclear cells were isolated from three groups: non-TB controls (n=31), TB controls (n=55), and MDR-TB patients (n=89).
  • Real-time PCR was used to measure the mRNA levels of P-pg and MRP.
  • One-way ANOVA and SNK q tests were employed for statistical analysis.

Main Results:

  • No significant difference was observed in P-pg mRNA levels among the three groups (MDR-TB: 1.34 ± 0.32, TB: 1.12 ± 0.23, non-TB: 1.05 ± 0.16; P > 0.05).
  • MRP mRNA levels were significantly higher in the MDR-TB group (3.45 ± 0.43) compared to the TB control group (1.23 ± 0.34) and the non-TB control group (1.04 ± 0.12) (P < 0.05).

Conclusions:

  • Elevated expression of MRP in PBMCs may be associated with multidrug resistance in TB patients.
  • MRP could be a potential biomarker for MDR-TB.

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...